Table 1. Baseline characteristics of 200 patients after liver transplantation for hepatocellular cancer included in the final study cohort.
| Characteristics | n (%) or median (IQR) |
|---|---|
| Recipient gender | |
| male | 143 (71.5%) |
| female | 57 (28.5%) |
| Recipient age (years) | 57 (52–61) |
| MELD | 11 (8–13) |
| HCV infection | 137 (68.5%) |
| HBV infection | 81 (40.5%) |
| Within Milan criteria | 120 (60.0%) |
| Within UCSF criteria | 144 (72.0%) |
| Within Up-to-7 criteria | 154 (77.0%) |
| Number of tumors | 1 (1–3) |
| Size of the largest tumor (cm) | 3.0 (2.0–4.5) |
| Total tumor volume (cm3) | 22.5 (5.3–54.2) |
| Pre-transplant AFP (ng/ml) | 16 (6–114) |
| Poor tumor differentiation | 24 (12.0%) |
| Microvascular invasion | 57 (28.5%) |
| Neoadjuvant treatment | 86 (43.0%) |
| Total ischemic time (hours) | 9.0 (8.0–10.3) |
| Piggyback transplantations | 175 (87.5%) |
| Intraoperative PRBC transfusions (units) | 3.0 (1.5–6.0) |
| Intraoperative FFP transfusions (units) | 7.0 (5.0–10.0) |
| Donor age (years) | 49.5 (38.0–57.5) |
IQR – interquartile range; UCSF – University of California, San Francisco; AFP – alpha-fetoprotein; MELD – model for end-stage liver disease; HCV – hepatitis C virus; HBV – hepatitis B virus; PRBC – packed red blood cells; FFP – fresh frozen plasma.